Skip to main content
NewslettersWatchlist

Vertex Pharmaceutic(VRTX-Q)
NASDAQ

Today's Change
Real-Time Last Update Last Sale Cboe BZX Real-Time
Day Low445.00
Day High455.43
Open:454.24
Price movement based on the high, low and last over the given period.
Previous Close
52-Week High/Low
Volume
Average Volume
Price/Earnings (TTM)
Forward Annual Dividend & Yield
Market Capitalization, $M
5-Day Change
Realtime quote and/or trade prices are not sourced from all markets.
Select a category then submit the form to load news
Motley Fool
3 Growth Stocks You Can Buy Right Now Without Any Hesitation
Motley Fool
2 Top Biotech Stocks to Buy Now and Hold For 5 Years or More
Motley Fool
Prediction: This Biotech Stock Is Heading for a Once-in-a-Generation Opportunity
Motley Fool
2 Biotech Stocks You Can Buy Hand Over Fist This Month
Barchart
1 Penny Stock to Grab Now for 183% Upside Potential
Barchart
Stocks Finish Higher as Chip Makers Rally
Barchart
Stocks Rally on Chip Stock Strength
Motley Fool
5 Top Stocks to Buy in November
Motley Fool
My 2 Favorite Growth Stocks to Buy Hand Over Fist in November
Motley Fool
Vertex Pharmaceuticals (VRTX) Q3 2024 Earnings Call Transcript
Motley Fool
Thinking of Buying CRISPR Therapeutics Stock? Watch These 2 Key Numbers
Baystreet
Canada Jobs on Agenda for Next Week
Motley Fool
12 High-Growth Stocks That Could Deliver Parabolic Returns
Motley Fool
The Smartest Growth Stock to Buy With $500 Right Now
Motley Fool
Vertex Pharmaceuticals Just Found Its Newest Blockbuster Drug. A $41 Billion Market Awaits
Motley Fool
Why We Buy Stocks
Motley Fool
Prediction: These 2 Stocks Will Beat the S&P 500 Through 2030
Barchart
This Biotech Stock Insider is Buying Shares, Should You?
Motley Fool
Got $1,000? 2 Magnificent Growth Stocks to Buy and Hold Forever
Motley Fool
3 No-Brainer Growth Stocks to Buy in October
Motley Fool
2 Biotech Stocks to Buy Hand Over Fist in October
Motley Fool
3 Top Stocks That Could Still Rocket Higher in 2024

Profile

Vertex Pharmaceuticals Incorporated is focused on the discovery, development, and commercialization of small molecule drugs targeting serious diseases. The company's main area of focus is cystic fibrosis. The company's lead marketed products are Trikafta, Symdeko/Symkevi, Orkambi and Kalydeco, which are collectively approved to treat the people with CF in North America, Europe and Australia. Trikafta, Vertex's triple combination regimen, was approved by the FDA for the treatment of CF in people aged 12 years and older who have at least one F508del mutation. While CF remains the main area of focus, Vertex is also developing treatments for sickle cell disease, beta thalassemia, APOL1-mediated kidney disease, type 1 diabetes, pain, alpha-1 antitrypsin deficiency and muscular dystrophies. Pimodivir/VX-787, for the treatment of influenza, was out-licensed to Janssen while oncology candidates VX-970, VX-984 and VX-803 were divested to Merck KGaA.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright ยฉ 2024.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).

Copyright ยฉ 2024 Morningstar. All Rights Reserved. The information contained herein: (1) is proprietary to Morningstar and/or its content providers; (2) may not be copied or distributed; and (3) is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information. Past performance is no guarantee of future results.